Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Dextran sulfate is poorly absorbed after oral administration.

Lorentsen KJ, Hendrix CW, Collins JM, Kornhauser DM, Petty BG, Klecker RW, Flexner C, Eckel RH, Lietman PS.

Ann Intern Med. 1989 Oct 1;111(7):561-6.

PMID:
2476054
2.

Pharmacokinetic analysis of dextran sulfate in rats as pertains to its clinical usefulness for therapy of HIV infection.

Hartman NR, Johns DG, Mitsuya H.

AIDS Res Hum Retroviruses. 1990 Jun;6(6):805-12.

PMID:
1694681
3.

Orally administered dextran sulfate is absorbed in HIV-positive individuals.

Hiebert LM, Wice SM, Jaques LB, Williams KE, Conly JM.

J Lab Clin Med. 1999 Feb;133(2):161-70.

PMID:
9989768
4.

Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection.

Flexner C, Barditch-Crovo PA, Kornhauser DM, Farzadegan H, Nerhood LJ, Chaisson RE, Bell KM, Lorentsen KJ, Hendrix CW, Petty BG, et al.

Antimicrob Agents Chemother. 1991 Dec;35(12):2544-50.

5.

Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Abrams DI, Kuno S, Wong R, Jeffords K, Nash M, Molaghan JB, Gorter R, Ueno R.

Ann Intern Med. 1989 Feb 1;110(3):183-8.

PMID:
2463780
6.

Low molecular weight dextran sulfate is well tolerated in humans and increases endogenous expression of islet protective hepatocyte growth factor.

Schmidt P, Magnusson C, Lundgren T, Korsgren O, Nilsson B.

Transplantation. 2008 Dec 15;86(11):1523-30. doi: 10.1097/TP.0b013e3181890593.

PMID:
19077884
7.

Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults.

Riddler SA, Wang LH, Bartlett JA, Savina PM, Packard MV, McMahon DK, Blum MR, Dunn JA, Elkins MM, Mellors JW.

Antimicrob Agents Chemother. 1996 Dec;40(12):2842-7.

8.

Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route.

Hiebert LM, Wice SM, Ping T.

Biomed Pharmacother. 2004 Jul-Aug;58(6-7):372-80.

PMID:
15271419
9.

Effects of oxypolygelatin and dextran 70 on hemostatic variables in dogs.

Glowaski MM, Moon-Massat PF, Erb HN, Barr SC.

Vet Anaesth Analg. 2003 Oct;30(4):202-10.

PMID:
12925177
10.

Determination of absolute amounts of heparin and of dextran sulfate in plasma in microgram quantities.

Jaques LB, Wice SM, Hiebert LM.

J Lab Clin Med. 1990 Apr;115(4):422-32.

PMID:
1691256
11.

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.

Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J.

Antimicrob Agents Chemother. 1995 Dec;39(12):2759-64.

12.

Effect of dextran sulfate on renal accumulation of gentamicin.

Kikuchi S, Aramaki Y, Nonaka H, Tsuchiya S.

Pharm Res. 1990 Jun;7(6):644-7.

PMID:
1694993
13.

Dextran sulfate disposition in the rat.

Foster BC, Gallicano KD, Whitehouse LW, McGilveray IJ, Khan SR.

Biopharm Drug Dispos. 1990 Oct;11(7):595-606.

PMID:
1702324
14.

Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.

Retlich S, Duval V, Ring A, Staab A, Hüttner S, Jungnik A, Jaehde U, Dugi KA, Graefe-Mody U.

Clin Pharmacokinet. 2010 Dec;49(12):829-40. doi: 10.2165/11536620-000000000-00000.

PMID:
21053992
15.

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

Stangier J, Stähle H, Rathgen K, Fuhr R.

Clin Pharmacokinet. 2008;47(1):47-59.

PMID:
18076218
16.

Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro.

Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E.

Proc Natl Acad Sci U S A. 1988 Aug;85(16):6132-6.

17.

Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects.

Nave R, Bethke TD, van Marle SP, Zech K.

Clin Pharmacokinet. 2004;43(7):479-86.

PMID:
15139796
20.

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.

Eriksson UG, Johansson S, Attman PO, Mulec H, Frison L, Fager G, Samuelsson O.

Clin Pharmacokinet. 2003;42(8):743-53.

PMID:
12846595

Supplemental Content

Support Center